324 related articles for article (PubMed ID: 21251382)
1. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
[TBL] [Abstract][Full Text] [Related]
2. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
3. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment.
de Jong TP
J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
[No Abstract] [Full Text] [Related]
5. Editorial comment.
Jorgensen TM
J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695626
[No Abstract] [Full Text] [Related]
6. Editorial comment.
Yang SS
J Urol; 2009 Oct; 182(4 Suppl):2038-9; discussion 2039. PubMed ID: 19695625
[No Abstract] [Full Text] [Related]
7. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
[TBL] [Abstract][Full Text] [Related]
9. Tolterodine for treatment of overactive bladder.
Kanofsky JA; Nitti VW
Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
[TBL] [Abstract][Full Text] [Related]
10. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
[TBL] [Abstract][Full Text] [Related]
11. Double anticholinergic therapy for refractory overactive bladder.
Bolduc S; Moore K; Lebel S; Lamontagne P; Hamel M
J Urol; 2009 Oct; 182(4 Suppl):2033-8. PubMed ID: 19695628
[TBL] [Abstract][Full Text] [Related]
12. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
Babu R
Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
[TBL] [Abstract][Full Text] [Related]
14. Contemporary treatment options for overactive bladder.
Taylor PH; Sussman DO
JAAPA; 2005 Nov; Suppl():3-13; quiz 14-5. PubMed ID: 16315503
[No Abstract] [Full Text] [Related]
15. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
18. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
19. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
